Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Batty · SciRah

Researcher profile · Semantic Scholar

N. Batty

Share profile

N. Batty — researcher profile on SciRah

h-index: 9
Works: 27
Citations: 646

Most-cited papers

Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
E. Jabbour, G. Garcia-Manero, N. Batty, Jenny Shan +5 more
2010Cancer264 citations Open access
Semantic Scholar
Histone deacetylase inhibitors as anti-neoplastic agents.
N. Batty, G. Malouf, J. Issa
2009Cancer Letters141 citations
Semantic Scholar
Prolonged duration of response in lenvatinib responders with thyroid cancer
A. Gianoukakis, C. Dutcus, N. Batty, M. Guo +1 more
2018Endocrine-Related Cancer81 citations Open access
Semantic Scholar
The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP
N. Batty, Elham Ghonimi, Lei Feng, L. Fayad +7 more
2012Clinical Lymphoma, Myeloma & Leukemia38 citations Open access
Semantic Scholar
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma
J. Chesney, S. Awasthi, B. Curti, L. Hutchins +11 more
2018Melanoma research37 citations
Semantic Scholar
Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data
Qiufei Ma, M. Shilkrut, Zhong-Yun Zhao, Minming Li +2 more
2018BMC Cancer21 citations Open access
Semantic Scholar
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
J. Chesney, Y. Imbert-Fernandez, S. Telang, M. Baum +3 more
2018Melanoma research18 citations Open access
Semantic Scholar
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study
N. Batty, F. Hagemeister, Lei Feng, J. Romaguera +6 more
2012Leukemia and Lymphoma12 citations
Semantic Scholar
Decitabine Is More Cost Effective Than Standard Conventional Induction Therapy In Elderly Acute Myeloid Leukemia Patients
N. Batty, S. Wiles, Mathew Kabalan, Rohit Sharma +11 more
20139 citations
Semantic Scholar
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States
Qiufei Ma, Yao-Zhu J. Chen, D. Hines, J. Munakata +3 more
2017Journal of dermatological treatment (Print)8 citations Open access
Semantic Scholar
Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies
N. Batty, Joseph Shatzel, S. Wiles, Mathew Kabalan +14 more
20144 citations Open access
Semantic Scholar
Economic Evaluations of Hematological Malignancies Compared with Solid Tumors
N. Batty, Joseph Shatzel, S. Wiles, Mathew Kabalan +14 more
20143 citations
Semantic Scholar
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.
N. Batty, N. Yarlagadda, R. Pili
2013The Journal of the National Comprehensive Cancer Network3 citations Open access
Semantic Scholar
Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
N. Batty, Elham Ghonimi, Lei Feng, A. Younes +7 more
20102 citations
Semantic Scholar
Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI
N. Batty, H. Kantarjian, G. Borthakur, F. Ravandi +5 more
20082 citations
Semantic Scholar
434PDImpact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
M. Tahara, M. Brose, L. Wirth, Takuya Suzuki +4 more
20171 citations Open access
Semantic Scholar
How to Calculate Better Our Financial Risk in Oncology
N. Batty
20141 citations
Semantic Scholar
Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
N. Batty, Ellen B. Kossoff, G. Dy
2012Journal of Experimental Pharmacology1 citations Open access
Semantic Scholar
Увеличенная длительность ответа на терапию ленватинибом у пациентов с раком щитовидной железы
Andrew G. Gianoukakis, Corina E. Dutcus, N. Batty, M. Guo +1 more
20180 citations Open access
Semantic Scholar
Journal of Cancer Epidemiology & Treatment A Need of Metrics in Cancer Economics: Myth or Hope
N. Batty
20150 citations Open access
Semantic Scholar
My Son's Second Birthday
N. Batty
2012Journal of Palliative Medicine0 citations
Semantic Scholar
Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP.
N. Batty, Elham Ghonimi, Lei Feng, L. Fayad +7 more
20120 citations
Semantic Scholar
Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma.
P. Jitawatanarat, R. Dawar, K. Chittawatanarat, N. Batty +2 more
20120 citations
Semantic Scholar
Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma.
Ellen B. Kossoff, N. Batty, A. Ceacareanu, K. Attwood +8 more
20120 citations
Semantic Scholar
ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study.
N. Batty, F. Hagemeister, J. Romaguera, M. Rodriguez +5 more
20100 citations
Semantic Scholar
Abstract 3812: Innate immunity in inflammatory breast cancer (IBC) patients: Clues from HLA profiling
N. Batty, Pedro Cano, Pamela A Alizadeh, S. Tin +5 more
20100 citations
Semantic Scholar
Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).
N. Batty, X. Badoux, M. Keating, E. Lin +7 more
20090 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Mclaughlin×5
Invite
P. Mclaughlin — researcher profile on SciRah
F. Hagemeister×5
Invite
F. Hagemeister — researcher profile on SciRah
Lei Feng×4
Invite
Lei Feng — researcher profile on SciRah
A. Younes×4
Invite
A. Younes — researcher profile on SciRah

×4

Invite

M. Rodriguez — researcher profile on SciRah

J. Romaguera×4

Invite

J. Romaguera — researcher profile on SciRah

F. Samaniego×4

Invite

F. Samaniego — researcher profile on SciRah

Invite

K. Attwood — researcher profile on SciRah

Invite

S. O'Brien — researcher profile on SciRah

Elham Ghonimi×3

Invite

Elham Ghonimi — researcher profile on SciRah

Invite

S. Wiles — researcher profile on SciRah

Mathew Kabalan×3

Invite

Mathew Kabalan — researcher profile on SciRah